This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Helen M. Shaw, PhD; William H. McCarthy, FRACS, MEd; Stanley W. McCarthy, FRCPA; Gerald W. Milton, FRCS, FRACS

Arch Surg. 1987;122(10):1147-1150.

Abstract
• Of 846 patients with stage I malignant melanoma that was less than 0.76-mm thick who were followed up for two to 31 years, 61 (7.2%) developed a recurrence. For those patients who did not initially undergo an elective lymph node dissection, the majority of first recurrences were at regional lymph nodes. Attempts have been made to identify those patients at risk of relapsing. Axial lesions, particularly those on the scalp, had the highest recurrence rate, with 15% of all thin scalp lesions recurring compared with only 4% of all thin extremity lesions. Three histological features proved to be useful prognostic indicators when analyzed by single-factor analysis. Evidence of ulceration in the primary lesion increased the recurrence rate from 6.7% to 26.1%. While only 4.3% of lesions displaying low mitotic activity recurred, this rate rose to 23.8% for those lesions of a high mitotic grade. Only 5% of Clark's level II lesions recurred, compared with about 12% of lesions at either level III or IV. Evidence of regression in thin lesions had no deleterious effect on prognosis. This study defines a small subset of patients who may benefit from elective lymph node dissection.

(Arch Surg 1987;122:1147-1150)

Author Affiliations
From the Sydney Melanoma Unit, Department of Surgery, The University of Sydney, Camperdown, Australia (Drs Shaw, W. H. McCarthy, and Milton); and Anatomical Pathology, Royal Prince Alfred Hospital, Camperdown, Australia (Dr S. W. McCarthy).

Footnotes
Accepted for publication Nov 17, 1986.

Reprint requests to Sydney Melanoma Unit, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW, 2050, Australia (Dr Shaw).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Malignant Melanoma in Turkey: A Single Institution's Experience on 475 Cases
Tas et al.
Jpn J Clin Oncol 2006;36:794-799.
ABSTRACT | FULL TEXT  

Metastatic Malignant Melanoma of the Gastrointestinal Tract
Liang et al.
Mayo Clin Proc. 2006;81:511-516.
ABSTRACT | FULL TEXT  

Sentinel Lymph Node Biopsy in Patients With Thin Melanoma
Lowe et al.
Arch Dermatol 2003;139:617-621.
ABSTRACT | FULL TEXT  

Current Status of Sentinel Lymph Node Mapping and Biopsy: Facts and Controversies
Jakub et al.
The Oncologist 2003;8:59-68.
ABSTRACT | FULL TEXT  

Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
Balch et al.
JCO 2001;19:3622-3634.
ABSTRACT | FULL TEXT  

Melanoma of the Scalp Presenting as Poliosis Circumscripta
Dunn et al.
Arch Dermatol 1995;131:618-619.
ABSTRACT  

Malignant Melanoma: Who Shall Live and Who Shall Die?
Rivers and Ho
Arch Dermatol 1992;128:537-542.
ABSTRACT  

A Community Study of Delay in Presenting With Signs of Melanoma to Medical Practitioners
Hennrikus et al.
Arch Dermatol 1991;127:356-361.
ABSTRACT